1 H NMR spectroscopy was performed with 2-ms echo time in the rat brain at 9.4 T. Frequency domain analysis with LCModel showed that the in vivo spectra can be explained by 18 metabolite model solution spectra and a highly structured background, which was attributed to resonances with fivefold shorter in vivo T 1 than metabolites. The high spectral resolution (full width at half maximum approximately 0.025 ppm) and sensitivity (signal-to-noise ratio approximately 45 from a 63-L volume, 512 scans) was used for the simultaneous measurement of the concentrations of metabolites previously difficult to quantify in 1 H spectra. The strongly represented signals of Nacetylaspartate, glutamate, taurine, myo-inositol, creatine, phosphocreatine, glutamine, and lactate were quantified with Cramér-Rao lower bounds below 4%. Choline groups, phosphorylethanolamine, glucose, glutathione, ␥-aminobutyric acid, Nacetylaspartylglutamate, and alanine were below 13%, whereas aspartate and scyllo-inositol were below 22%. Intra-assay variation was assessed from a time series of 3-min spectra, and the coefficient of variation was similar to the calculated Cramér-Rao lower bounds. Interassay variation was determined from 31 pooled spectra, and the coefficient of variation for total creatine was 7%. Tissue concentrations were found to be in very good agreement with neurochemical data from the literature.
INTRODUCTION
The usefulness of localized in vivo 1 H NMR spectroscopy at long and short echo times has been demonstrated in many studies of the brain and its disorders, e.g., in hepatic encephalopathy, Alzheimer's, Huntington's, and Parkinson's diseases, acute traumatic brain injury, and dementia (1, 2) . When using long echo times (Ͼ100 ms), spectra are simplified and the dominant singlet peaks of the methyl groups are readily observable. Most 1 H NMR investigations in vivo have focused on detecting changes of the methyl signals of, N-acetylaspartate (NAA), 1 total creatine (Cr ϩ PCr), choline (Cho), and lactate (Lac) (3) (4) (5) . Short-echo-time in vivo 1 H NMR spectra contain more information, i.e., increased signal contributions of coupled spin systems such as glutamate (Glu), glutamine (Gln), myo-inositol (Ins), glucose (Glc), and taurine (Tau). The ensuing spectral overlap requires sophisticated approaches for the separation of the metabolite signals. Furthermore, contributions of broad signals with short T 2 become increasingly apparent as an underlying "baseline" throughout the whole 1 H NMR spectrum (6 -9) .
A wealth of neurochemical information can be gained from high-resolution NMR spectroscopy. Identification and assignment of resonances has been performed, e.g., in perchloric acid extracts, extracted tissue, immobilized cells, and in animals and humans in vivo by 2D-H,C-HSQC, 2D COSY, J-resolved 1 H NMR experiments, and one-dimensional multinuclear approaches (10 -17) . In vivo 1 H NMR spectra have been quantified using several different approaches, such as time domain analysis combined with prior knowledge (18, 19) , frequency domain analysis (20) , or combinations thereof (21) , as well as principal component analysis, wavelet analysis, or genetic algorithms (22) (23) (24) (25) .
It has been recently demonstrated that the spectral resolution in 1 H NMR spectra in vivo increases significantly with static magnetic field, suggesting substantial improvements in sensitivity for the determination of previously unresolved signals (26) . The purpose of the present study was to demonstrate that such gains can be realized in the rat brain in vivo at 9.4 T and to quantify the overall 1 H spectrum by LCModel analysis (20) . Exploiting the improvements and stability recently achieved with a 1-ms echo time STEAM sequence (27) , a further aim was to determine whether the underlying baseline resonances
Interface software for data conversion and processing was written with PV-WAVE (Visual Numerics, Inc., Boulder, CO), which allowed automated frequency and phase correction and automated peak integration of the metabolite spectra. In some spectra the residual water signal was removed in the time domain using the Lanczos HLSVD routine (accelerated version of state-space HSVD) from the MRUI 97.1 software package (32) .
Quantification was based on frequency domain analysis using LCModel (linear combination of model spectra of metabolite solutions in vitro, version 5.1-7W) (20) . In vivo spectra were analyzed by a superposition of a set of in vitro basis spectra by means of a constrained regularization algorithm finding the best compromise between lineshape and baseline consistent with the data. The method uses the experimentally determined spectral pattern of each metabolite without further analysis.
In vitro spectra were collected from Ala, Asp, GPC, PC, Cr, PCr, GABA, Glc, Gln, Glu, GSH, Ins, Scyllo, Lac, NAA, NAAG, PE, and Tau. All chemicals were purchased from Sigma (St. Louis, MO). Aqueous solutions of 50 mM concentration of the metabolites were prepared in 100 mM phosphate buffer with 0.2 mM of 2,2-dimethyl-2-silapentane-5-sulfonate as the chemical shift reference (␦ ϭ 0.0 ppm). For cholinecontaining compounds the phosphate buffer was replaced by 100 mM sodium chloride. The pH was adjusted to 7.10, and temperature was maintained at 37°C by warm water circulation using a heating blanket and verified by a thermosensor.
In vivo spectra were referenced to the methyl signal of NAA (␦ ϭ 2.009 ppm) and the inversion recovery spectra to the macromolecule M1 resonance (␦ ϭ 0.916 ppm). In vitro model spectra were calibrated by integrating the 1 H metabolite resonances and by adjusting the nominal concentrations for the LCModel input. In vivo metabolite concentrations were determined using the intensity of the water signal measured at echo time TE ϭ 2 ms as an internal standard and assuming a constant tissue water content of 83% for the rat brain (33) and a 100% visibility of the water signal. This procedure accounted for different voxel sizes, spatial variation of sensitivity of the surface coil, and different coil loadings. Metabolite concentrations were expressed as micromoles per gram wet weight (ww). The effect of potential animal motion on the summed signal was assessed to be below 0.5% by measuring the phase and amplitude stability of single-shot water signals. In the LCModel fit, only a zero-order phase correction was performed resulting from proper timing of the first sampled data point in the pulse sequence. Eddy-current effects were minimal and the field drift was less than 1 Hz. An extended spectral range for LCModel's finite discrete convolution was chosen to account for the in vivo Lorentzian lineshape with long tails due to the very good shimming.
spectra. In Fig. 1 the measured and fitted spectrum are shown together with the residuals and the spline baseline as determined by LCModel. The numbers indicate more than 40 detected resonances, which are assigned in Table 1 . Although the determined metabolite concentrations were consistent with previous neurochemical measurements and had reasonable errors, a significantly varying baseline remained, despite excellent water suppression and suppression of signals from outside the
FIG. 1.
LCModel analysis of a short-echo-time 1 H NMR spectrum of the rat brain in vivo including 18 metabolite model spectra (TE ϭ 2 ms, TM ϭ 20 ms, TR ϭ 6 s, 512 scans, 63-L volume). Shown is the in vivo spectrum (top), the fitted spectrum with spline baseline (bottom), and the residuals (middle trace). The assignment of the peaks corresponds to the numbers in Table 1 . Only FT and zero-order phase correction was applied (no weighting function).
volume of interest. The apparent structure of the spline baseline suggested the presence of biological signals underlying the narrow metabolite peaks, consistent with previous reports of large molecular weight compounds contributing to the spectrum of brain extracts (14) with relatively short T 1 and T 2 compared with acid-extracted metabolites. We therefore further assessed potential macromolecule contributions to the in vivo spectrum and the effect on the quantification of including a measured macromolecule spectrum to the LCModel approach. Note. 1 H chemical shifts were referenced to the N-acetylaspartate methyl peak. The assignment was based on LCModel analysis containing model solution spectra. Chemical shifts were determined from peak positions in vivo and from the fitted model spectra with an accuracy of Ϯ1 Hz (Ϯ0.003 ppm).
Baseline in 1 H Spectra
T 1 values of rat brain metabolites in vivo at 9.4 T ( Table 2) were determined from the inversion recovery experiment shown in Fig. 2 . To minimize confounding effects of the underlying macromolecule (MM) resonances with shorter T 2 , the echo time (TE) was set to 100 ms. The signals of the NAA, Cr ϩ PCr, and Cho methyl peaks as well as those from Tau were minimized when the inversion time t IR was between 0.93 and 0.98 s, whereas the Cr ϩ PCr methylene resonances were minimized at the significantly shorter t IR of 0.61 s. The T 2 values for these metabolites were fitted by log-linear regression of a series of 11 spectra acquired with equally spaced echo times between 100 and 200 ms (data not shown), resulting in T 2 values between 91 and 147 ms ( Table 2) .
To determine the macromolecule contributions in shortecho-time spectra in vivo, the nulling time after the inversion pulse, t IR null , was set to 0.95 s according to Table 2 . The spectra acquired with TE ϭ 2 ms and TE ϭ 20 ms using this t IR null ( Fig.  3) represent mostly macromolecule signals which have been reported with short T 1 (14) . Major resonances were observed at 0.916 ppm (labeled M1, which was used as reference), 1.21 (M2), 1.39 (M3), 1.67 (M4), 2.04 (M5), 2.26 (M6), and 2.99 ppm (M7). In addition, we also consistently observed resonances at 3.21 (M8), 3.77 (M9), and 4.29 ppm (M10). When increasing TE to 20 ms these macromolecule signals were reduced by approximately 50% relative to TE ϭ 2 ms (bottom spectrum in Fig. 3 ). Note that the narrow peak at 3.925 ppm was assigned to the incompletely suppressed Cr ϩ PCr methylene resonances, for which T 1 was 40% reduced compared to the other metabolites ( Table 2 ). The T 2 of the macromolecule signals, T 2 MM , was estimated from the two spectra shown in Fig.  3 to be approximately 26 ms. T 1 of the resolved macromolecule peaks, T 1 MM , was estimated from an inversion recovery experiment (t IR ϭ 160 -340 ms) to be approximately 300 ms (data not shown). Both relaxation times were three to six times shorter than those of the metabolites, which can be used for a separation of signals based on the different relaxation properties.
To further minimize contributions from metabolite signals to the spectrum with t IR null ϭ 0.95 s, the Cr ϩ PCr methylene resonance was eliminated in the time domain using HLSVD analysis and by applying exponential multiplication corresponding to a linebroadening of 20 Hz. The residual contribution of metabolite signals with the T 1 in the range of 1.32-1.42 s was estimated to be Ϯ2% of the fully recovered intensity and the effect on quantification was therefore considered negligible.
The MM basis spectrum, used for the analysis of the 2-ms echo-time 1 H spectrum in Fig. 1 , is shown in Fig. 4 (solid curve) and compared to the spline baseline of Fig. 1 obtained when the MM spectrum was omitted from the basis set (dashed curve). The default minimal knot spacing of 0.1 ppm for the LCModel regularized spline baseline allowed enough flexibility at most spectral resolutions, S/N, and TE. To account for the rapidly varying baseline (Fig. 4, dashed Note. T 1 and t IR null were fitted from the data shown in Fig. 2 . To determine T 2 , the echo time was varied by TE ϭ 100 -200 ms (increment 10 ms) and peak integrals were fitted by log-linear regression.
spacing was further reduced to 0.05 ppm, based on the linewidth of the macromolecule peak M1 (approximately 0.1 ppm). When the MM spectrum was included in the basis set, the minimal knot spacing was increased to 0.25 ppm. As can be seen from Fig. 4 (solid curve), the spline baseline mimicked the MM peaks very well. In vivo, inclusion of the MM basis spectrum consistently flattened and reduced the residual spline baseline substantially.
The comparison of the experimentally based MM background to the fitted spline baseline shown in Fig. 4 demonstrates that the latter reproduces the MM spectrum very well for the resolved macromolecule peaks M1-M4 as well as M5, M7, and M8 underneath the NAA, Cr ϩ PCr, and Cho methyl peaks. However, even with a tight knot spacing of 0.05 ppm, the spline baseline could not completely reproduce all features of the in vivo MM spectrum. For example, a significant underestimation was observed at M6 (2.26 ppm) and around 1.9 ppm, which led to a 230% overestimated GABA concentration. Likewise M5, M7, and M8 were underestimated leading to slightly higher concentrations of NAA, Cr, and Cho. Overall, the concentrations and corresponding Cramér-Rao (CR) lower bounds tended to be approximately 6% higher when using the spline baseline only.
Quantification and Assignment in Short-Echo-Time Spectra
The in vivo 1 H NMR spectrum of Fig. 1 was analyzed with the 18 metabolite solution spectra and an experimentally determined macromolecule model spectrum (Fig. 5) . Quantitative results are shown in Table 3 together with comparative neurochemical data from the literature (13, (33) (34) (35) (36) (37) (38) (39) (40) . The comparison of the in vivo with the fitted data (TE ϭ 2 ms) shows that the solution model metabolite spectra (with a long T 1 ) together with the MM spectrum (short T 1 ) account for most spectral features ( (14) and are extended by M8 (3.21), M9 (3.77), and M10 (4.29). Due to faster relaxation (see Fig. 2 ), the creatine and phosphocreatine methylene resonance at 3.93 ppm with the distinct narrow linewidth was not completely eliminated. The spectra were processed with 6 Hz Lorentzian linebroadening.
FIG. 4.
Comparison of the LCModel spline baseline (dashed curve) and the measured metabolite-nulled spectrum (Figs. 1 and 5 ). The agreement of the spline with the experimental macromolecule spectrum is excellent despite the fact that no prior knowledge has been included in the spline baseline. The main differences of the spline are smoothing at positions 3.2, 3.0, 2.7, 2.25, 2.0, and 1.9 ppm, which may lead to an overestimation of NAA, Cr, Cho, and GABA concentrations compared to the inclusion of a macromolecule basis spectrum in the analysis.
butions from other compounds such as glucose at 3.4 ppm contribute minor spectral features to that region. The coupling pattern, relative intensities, and frequencies of the myo-inositol resonances were in excellent agreement with the model spectrum. A highly structured pattern of the NAA signals was discernible at 2.489 and 2.674 ppm corresponding to the two magnetically nonequivalent ␤CH 2 protons. Several peaks were recognized in the region 3.3-3.2 ppm, which were explained by contributions from Tau, Ins, Glc, and PE that could be deconvoluted from the choline methyl peak of GPC ϩ PC at 3.209 ppm. The concentration ratio of NAA relative to total creatine was [ A feature of 1 H NMR spectra acquired from the dog and rat brain in vivo at 9.4 T was a partially resolved peak at 3.98 ppm (26, 27) . In that region, PE has coupled signals as does serine (Ser) (Fig. 7) . The resolution-enhanced rat brain in vivo spectrum in Fig. 8 showed that the spectral pattern of PE with resonances at 3.98 and 3.22 ppm matched the in vivo spectrum between the Ins (4.060 ppm) and the PCr and Cr (3.931, 3.911 ppm) peaks with respect to chemical shift and lineshape (second trace). In contrast, Ser had resonances at 3.98 -3.94 and 3.83 ppm (third trace in Fig. 7 ). Nearby peaks from Lac, PCr, Cr, Gln ϩ Glu, Scyllo, and GPC ϩ PC had clearly different resonance positions. When both PE and Ser were included in the LCModel analysis, concentrations of PE were 1.5-1.7 mol/g ww (CR ϭ 8 -11%) and concentrations of Ser were 0.2-0.6 mol/g ww (CR ϭ 41-73%). Because Ser concentrations were much less consistent and found with a high CR error, a major contribution of Ser was not evident and thus Ser was omitted from the set of model spectra.
The strongly represented metabolites NAA, Cr, PCr, Tau, Ins, Glu, Gln, and Lac were estimated with Cramér-Rao lower
FIG. 5. LCModel analysis of a short-echo-time
1 H NMR spectrum of the rat brain in vivo (TE ϭ 2 ms, TM ϭ 20 ms, TR ϭ 6 s, same data as in Fig. 1 ). Shown is the spectrum (thin solid curve), the fit (thick solid curve), the fitted macromolecule spectrum (dashed curve), and the residuals (top). In the spectral region from 1.8 to 0.7 ppm, containing mostly macromolecule resonances, the fitted contributions of alanine and lactate are shown. Note the slowly varying spline baseline (dotted curve).
bounds below 4%, weaker metabolites below 13%, e.g., 6% for GPC ϩ PC, 6% for PE, 8% for GSH, and 12% for GABA, and Asp and Scyllo below 22% (see Table 3 for a detailed listing).
An analysis of a spectrum with increased TE ϭ 20 ms but otherwise identical experimental conditions is shown in Fig. 8 . Due to T 2 relaxation, an overall decreased intensity of the metabolites and the macromolecule resonances was discernible. In addition, J-modulation led to an altered spectral appearance compared to TE ϭ 2 ms (Fig. 6 ) that was very well reproduced by the model solution spectra for, e.g., NAA and ASP.
To assess the influence of the echo time TE and repetition time TR on the quantification, the LCModel results of three different measurements were compared with (A) TE ϭ 2 ms, TR ϭ 6 s, (B) TE ϭ 20 ms, TR ϭ 6 s, and (C) TE ϭ 20 ms, TR ϭ 4 s. Increasing TE from 2 to 20 ms with the same TR decreased the concentrations of total creatine, [Cr ϩ PCr], by 6%, [NAA] by 4%, and on average over all metabolites by 4%. Decreasing TR from 6 to 4 s further decreased the concentrations of [Cr ϩ PCr] by an additional 6%, [NAA] by 7%, and on average by 5%. However, the ratio [NAA]/[Cr ϩ PCr] remained constant within 3%, reflecting the similar relaxation times of creatine and NAA. The average concentration correction factor due to the T 2 relaxation at TE ϭ 2 ms was estimated to be less than 1%, which was well within the experimental variation.
Reproducibility
The error estimates from the standard least-squares covariance matrix (Cramér-Rao lower bounds (20) ) are lower bounds of the experimental variance because they are based on several assumptions. The most critical assumption is that the model is correct (or at least contains sufficient parameters to describe the data within experimental error). For instance, the Cramér-Rao lower bounds can be unrealistically low for insufficiently parameterized models.
Therefore, a direct experimental measure of the precision of the estimates, the intra-assay variation, was determined with a time series (1 h 45 min total measurement time) acquired with 32 blocks of 3-min acquisitions each using TE ϭ 20 ms and TR ϭ 6 s to compare the Cramér-Rao lower bounds with the standard deviation of the series. Table 4 shows that the coefficients of variation (CV) of the strongly represented metabolites (PCr, Cr, Glu, Ins, NAA, Tau) were below 5%, and for the weaker metabolites (GPC ϩ PC, Glc, Gln, GSH, Lac, PE) below 12%. The CV were in excellent agreement with the Cramér-Rao lower bounds for a single 3-min spectrum (32 Table 3 . Only FT and zero-order phase correction was applied to the in vivo data (no weighting function). scans), i.e., 2% for NAA, 7% for Cr, 6% for PCr, 4% for Glu, 4% for Ins, and 6% for Tau. The fact that CR are very close to CV suggests that our model closely approximates the information content of the in vivo situation. When averaging four 3-min spectra (128 scans), the errors were reduced approximately twofold, as can be seen in column 5 of Table 4 . In these 13-min spectra, most metabolites were detected with a CV below 8%, and variation of total creatine was on the order of 1%. The accuracy of several weak metabolites was also significantly improved, i.e., CV was 11% for Scyllo, 14% for GABA, 18% for Ala, and 26% for Asp.
The interassay reproducibility was determined by analyzing spectra measured under similar conditions, whereby experimental parameters were chosen to be TE ϭ 20 ms and TR ϭ 4 s to facilitate comparison with other studies at short echo times. Deliberately, all 31 spectra acquired from 20 animals were used without exclusions. A wide range of linewidth (FWHM ϭ 0.025-0.041 ppm) and signal-to-noise ratio (S/N ϭ 18-38) was, therefore, present in the data. To compare with previous analyses in Refs. (19, 41) and to reduce uncertainties of the quantification, concentrations were determined relative to the total creatine concentrations. The experimentally determined average value was 7.78 mol/g ww (CV ϭ 7.4%, relative to water at TE ϭ 2 ms), which was not corrected for T 1 and T 2 and thus underestimates the true concentration by at least 10%. The coefficients of variation for NAA, Glu, Cr, PCr, GSH, and PE were below 10%, and for Ins, Glc, Tau, GPC ϩ PC, Lac, and Ala below 20% (Table 5) , demonstrating the consistency and robustness of the LCModel analysis. The reliability was much higher in the analysis of higher quality spectra using 2-ms echo time, such as those shown in Figs. 5 and 6, with excellent shimming (FWHM ϭ 0.026 ppm), and high signal-to-noise ratio (S/N ϭ 45).
To assess the influence of the quality of shimming on metabolite determinations, the linewidths were artificially increased by applying additional exponential multiplication to the FID before the LCModel analysis. Progressive linebroadening of the 2-ms echo-time 1 H spectrum ( Fig. 5 ) from 0 to 30 Hz decreased the correlation coefficient between Cr and PCr linearly from Ϫ0.71 to Ϫ0.92, thus demonstrating the increasing difficulty of distinguishing Cr from PCr. The correlation coefficient of GPC and PC without additional linebroadening was Ϫ0.87, which is already close to Ϫ1. When linebroadening was applied, GPC was not detectable any more, suggesting that the concentrations of GPC and PC were difficult to determine separately, but the sum [GPC ϩ PC] remained highly reliable (see Table 3 ).
Applications: Hyperglycemia and Hepatic Encephalopathy
To quantify the glucose concentration in the rat brain, the spectral region of the LCModel analysis was extended through the water region to 5.4 ppm to include the ␣-Glc [1]CH resonance at 5.226 ppm. Hyperglycemia was induced by infusion of glucose at a constant rate of 4 mg/min. The comparison of the in vivo 1 H NMR spectrum with the fitted glucose spectrum (Fig. 9) shows that in addition to the resonance at 5.226 ppm, partially resolved peaks at 3.87, 3.83, 3.49, and 3.46 ppm (dotted lines) from the Glc spectrum were discernible. A small water peak that remained after water suppression (dashed curve) was fitted by HLSVD and removed in the time
FIG. 7. Resolution-enhanced
1 H NMR spectrum of the rat brain in vivo in the spectral region from 4.2 to 3.1 ppm (TE ϭ 20 ms, same data as in Fig. 8 , shifted sine-bell function). Model solution spectra of phosphorylethanolamine, serine, myo-inositol, taurine (dotted), and glucose (dashed) were processed with 2 Hz Gaussian linebroadening. The spectral patterns are in excellent agreement with the in vivo data with the exception of serine. Peak separation of PCr and Cr can be recognized at 3.9 ppm. The contributions of myoinositol-, taurine-, and choline-containing compounds are clearly discernible at 3.3-3.2 ppm.
FIG. 8. In vivo
1 H NMR spectrum from the same animal and voxel as in Fig. 6 , but at longer echo time TE ϭ 20 ms. The signal intensity is significantly decreased compared to Fig. 6 due to T 2 relaxation. The spectral pattern, e.g., of NAA or Asp ␤CH 2 resonances, is altered due to J-evolution. 114 domain to keep the residual around the water region low. The Glc concentration in this spectrum was 5.2 mol/g ww (CR ϭ 4%). An LCModel analysis that did not include the ␣-Glc C1 resonance at 5.226 ppm yielded the same result within 2%, consistent with the detection of several discernible glucose resonances in the upfield side of the spectrum at 9.4 T. In addition, after progressively linebroadening from 0 to 30 Hz of the hyperglycemic rat spectrum, the LCModel analysis did not reveal a significant difference whether the ␣-Glc C1 resonance at 5.226 ppm was included, but a general decrease in the concentration was observed unless the concentration was referenced to Cr ϩ PCr.
A 1 H NMR spectrum with 2-ms echo time of a pathological rat brain is shown in Fig. 10 as an example of quantification of elevated glutamine (26, 42) . Glutamine was increased threefold compared to normal brain (7.2 mol/g ww, CR ϭ 2%), whereas myo-inositol (2.1 mol/g ww, CR ϭ 6%) and choline-containing compounds GPC ϩ PC (0.31 mol/g ww, CR ϭ 13%) were decreased by approximately 50%. All other metabolites, including glutamate, were in the range of the values measured from the healthy rat brain shown in Table 3 .
DISCUSSION
This study shows that the detailed features of short-echotime in vivo spectra can be explained as a superposition of solution model spectra plus a background consisting of fast relaxing resonances (Figs. 5 and 6 ). The residual spline baseline was nearly negligible and thus, based on neurochemical extract data, no assumptions about major unknown metabolite contributions were needed to explain the in vivo data. Remarkable is the capability of LCModel to account for distorted baselines (43) or lineshapes, which may be caused by, e.g., eddy currents or a not fully suppressed water resonance. Despite excellent shimming, outer volume suppression, and a well-defined localization that minimized experimental artifacts, the fitted LCModel spline baseline of our in vivo 1 H spectra (Fig. 1) was very structured and nonnegligible. This observation supports previous findings that macromolecules with short T 1 and T 2 are detected in vivo by 1 H spectroscopy (14, 44 -46) . Note. The concentrations were not corrected for T 2 -related signal decay. Spectra were acquired from one animal during an overall 105-min experiment (TE ϭ 20 ms, TM ϭ 20 ms, TR ϭ 6 s). Blocks of 32 and 128 scans were analyzed with LCModel and the concentrations were averaged (S/N ϭ 20 and 35). Note. The concentrations were not corrected for T 1 -and T 2 -related signal decay. Metabolite concentrations were determined relative to [Cr ϩ PCr] ϭ (7.78 Ϯ 0.58) mol/g ww (CV ϭ 7%) and were excluded from the total pool of measurements (n ϭ 31) when the Cramér-Rao lower bounds of the LCModel analysis exceeded 35%. FWHM ϭ 0.031 Ϯ 0.004 ppm, S/N ϭ 28 Ϯ 5 (mean Ϯ SD).
a All rats with glucose infusion were excluded from the analysis.
Baseline in Short-Echo-Time Spectra
The metabolite T 2 values were between 100 and 150 ms (Table 2) , consistent with previous in vivo reports at 7-9.4 T (47-49). Longer T 2 (180 -260 ms) was reported at 4.7 T (50). Since the macromolecule T 2 MM was several times shorter at 9.4 T, i.e., approximately 26 ms, their contribution to the spectrum could be minimized by using longer echo times, e.g., TE ϭ 100 ms (Fig. 2) , at the expense of increased sensitivity to T 2 changes and reduced information content. At short echo times the macromolecule background is present in the entire 1 H chemical shift range from 4.3 to 0.8 ppm, i.e., approximately 10% of the MM signals are still left at TE ϭ 60 ms. From the resolved macromolecule intensities of the M1-M4 peaks, the overall macromolecule contributions to the 1 H spectrum can be assessed, provided that outer volume contaminations have been minimized. In our experimental setup, excellent localization with outer volume suppression was achieved using methods reported elsewhere (27) .
The metabolite T 1 values of the CH 3 groups (approximately 1.4 s, Table 2 ) measured at 9.4 T were similar for Cho, Cr, and NAA and lie in the range of those (1.4 -1.9 s) reported at 7 T (48) and 4.7 T (50). However, the macromolecule T 1 MM ϳ 300 ms was considerably shorter, which was exploited to determine the macromolecule background at 2-ms echo time, consistent with previous studies (45, 46) . As shown in Fig. 3 , our results and peak positions of the macromolecules, observed between 4.3 and 0.5 ppm, agreed very well with previous studies of rat and human brain tissue separating low-and high-molecularweight cytosolic fractions (14) . In addition, the diffusion coefficient of the macromolecules was found to be 50 times lower than that of freely diffusing water (51) , which corresponds to their large molecular weight.
The additional spline baseline with wide knot spacing of 0.25 ppm can be interpreted as a weight of the MM model spectrum in different spectral regions, which may be attributed to small T 1 differences within the MM resonances. This can, for instance, be seen in Fig. 5 , where the residual spline baseline is higher at ϳ3.7 ppm and lower at ϳ2.5 ppm. Including an experimentally measured MM spectrum in the LCModel analysis reproduced all major in vivo spectral features, with the exception of ASP at 2.79 ppm, which may have been underestimated due to a strong peak at 2.68 ppm in the MM spectrum, which might be a residual of the NAA ␤CH 2 resonance with shorter T 1 .
Principally, a systematic error in the MM baseline might be introduced by an incomplete nulling of the metabolite signals at a given t IR null . Incomplete nulling can be caused by differences in the metabolite T 1 at TE ϭ 2 ms from T 1 of Cr and NAA at 
FIG. 9.
1 H NMR spectrum of the rat brain in vivo during glucose infusion (4 mg/min) and fitted glucose model spectrum. LCModel analysis was performed in the spectral region up to 5.4 ppm including the ␣-Glc H1 resonance at 5.226 ppm (TE ϭ 20 ms, TM ϭ 20 ms, TR ϭ 4 s). The brain glucose concentration was determined to be 5.2 mol/g ww (CR ϭ 4%). Note the excellent agreement of the fine structure of the fitted glucose model spectrum with the in vivo data (dotted lines). The residual water signal at 4.65 ppm (dashed curve) was removed in the time domain prior to the analysis with LCModel. Only FT and zero-order phase correction was applied to the in vivo data (no weighting function).
TE ϭ 100 ms (Fig. 2) . The nulling times of Glu, Gln, Ins, Tau, or GABA were not found to be different in a series of shortecho-time spectra with inversion times from 0.1 to 3 s. Residual coupling patterns were not observed using resolution enhancement of the spectrum at t IR null ϭ 0.95 s (data not shown). Except for the shorter T 1 for the methylene Cr ϩ PCr at 3.9 ppm, there was no experimental evidence that relaxation times vary substantially among the metabolites. This is supported by the observation that T 1 for Cr was found to be comparable to that of GABA at 4 T in the human brain (46) , to that of Glc in the human brain (52), and to T 1 of Glu in the rat brain at 7 T (48). The spline baseline overall represented the macromolecule signals well, which further supports the notion that residual narrow metabolite signals are minor in metabolite-nulled spectra.
Quantification
Comparison of the metabolite concentrations obtained at 9.4 T from the rat brain in vivo with neurochemical literature mostly from the rat brain (Table 3) showed very good overall agreement. However, a direct comparison to the neurochemical concentrations may be subject to different experimental conditions such as different animals, regional variability of the metabolite concentrations, or methodological uncertainties of the extraction process as pointed out in, e.g., Ref. (13) . The concentrations of Ala, Cho, Cr, PCr, NAA, PE, and Tau were highly consistent with the neurochemical literature data, whereby our in vivo quantification was based on the assumption of a constant tissue water content of 83% (internal water reference). The concentrations of Asp, GABA, Gln, Glu, and GSH were comparable as well, but tended to provide lower values than the literature data. Although in the high-quality spectra (Figs. 6 and 7 ) the concentrations of Gln relative to Cr ϩ PCr were not changed between TE ϭ 2 and 20 ms, it was observed that in the medium quality spectra with TE ϭ 20 ms (Table 5 ) the Gln concentration was decreased and had a relatively large interassay standard deviation. This points to the fact that, even at 9.4 T, quantification of Gln was difficult without excellent shimming. The concentrations of Lac tended to be higher than in the literature (about 1.5-2.5 mol/g ww) and revealed some variability between animals. For Tau, the literature data show a considerable variation, because its concentration strongly depends on the area in the brain (33) , which may be true for Gln, too.
The serine contribution was found to be insignificant in the spectra compared to PE. Evidence for the presence of a PE signal in 1 H NMR spectra was found in the literature: 2D 1 H J-resolved spectra of extract data (13) revealed a compound near 4.0 ppm (not assigned) with a homonuclear coupling of J HH ϳ 5 Hz and a small heteronuclear splitting ( J PH ), which matches our solution spectrum of PE ( J HH ϭ 5.0 Hz, J PH ϭ 7.2 Hz). A cross peak of PE with coordinates (4.0, 3.2 ppm) was detected in 2D 1 H COSY experiments in rat brain tumors in vivo (53). In vivo 31 P NMR studies as well as neurochemical data showed a considerable contribution of PE in the brain on the order of 2 mM (33, 54, 55) . Further experiments are needed to determine relative contributions of glycerophosphorylethanolamine to the 1 H NMR resonance at 3.98 ppm in vivo (56, 57).
Quantification of glycine, another important neurotransmitter, which is present in significant concentrations in the brain, was difficult, because the singlet resonance at 3.55 ppm overlapped with the [1, 3] CH inositol resonance. Using long echo times or two-dimensional methods, e.g., CT-PRESS for effective homonuclear decoupling, may be needed to distinguish the glycine signal in vivo (58, 59) .
The influences of T 2 on quantification are difficult to unravel and depend on the experimental parameters used. In the model spectra, T 2 was so long (Ͼ600 ms) that its effect on the signals at short echo time was negligible. Cr and NAA signals were attenuated in vitro by approximately 4 and 2% at TE ϭ 20 ms. Considering that T 2 was shorter in vivo (ϳ100 ms) and showed inter-and intrametabolite variations, a correction factor for each metabolite concentration was, therefore, not trivial to determine even at short echo times of TE ϭ 20 ms. Measurements of the metabolite signals and the water reference at TE ϭ 2 ms minimized such effects.
An excellent match between the in vitro spectral patterns with the in vivo data was achieved by carefully adjusting pH of the metabolite model solutions and by controlling the temperature. For example, the Cr methylene resonance shifted by approximately 0.1 Hz/°C, which affected the analysis at 9.4 T, since the separation of the Cr and PCr methylene signals was only 8 Hz in vivo. The chemical shifts of the myo-inositol multiplets changed by less than 0.3 Hz/°C, which nevertheless influenced multiplet intensities due to higher order spin effects.
The total creatine, NAA, and the sum of Gln ϩ Glu concentrations measured at TE ϭ 20 ms (Table 3 to 5) agree well with a previous study that used the LCModel approach in the rat brain in vivo at 2.35 T (41). In our study, the Tau concentration was higher and Cho lower, which can be explained by the reduced resolution between Tau-Cho and a concomitant increase in the Cramér-Rao lower bounds at lower fields. Coefficients of variation in the current study were up to eight times smaller when correcting for differences in voxel size. Such increases in sensitivity can only partially be explained by the increase in static field, since the improved resolution significantly contributes to the overall sensitivity. This is evident when considering, for instance, that total creatine exhibits a 4-fold increase in sensitivity, which is half that observed for myo-inositol. The importance of the spectral resolution in improving sensitivity can be further appreciated when considering that at 9.4 T PCr is now a separately quantifiable metabolite, which could be interpreted either as an at least 100-fold gain in SNR for PCr or simply that the number of identified metabolites was dramatically increased. Therefore, many metabolites can be more reliably assessed at high magnetic fields due to their increasingly distinguishable representation in the spectra, e.g., PCr and Cr, Gln and Glu, Tau and Cho, PE, GABA, GSH, and Ala.
A recent study using time domain fitting in the rat brain in vivo at 4.7 T (TE ϭ 16 ms) included the major metabolites NAA, Glu, Gln, Cr, Cho, Glc, and Ins (19) , which agreed with our measurements within their large interassay variation. A much higher Cho concentration of 0.2-0.3 times of [Cr ϩ PCr] was reported, which can be explained by the absence of taurine in their analysis. Quantification of glutamine at 4.7 T in the rat brain yielded a CR of 100% suggesting a low reliability. The ability to detect the changes of glutamine in the human brain at 4 T much more accurately (26) further illustrated the advantages of excellent shimming. At 9.4 T, the glutamine and glutamate ␥CH 2 resonances were fully separated and the ␤CH 2 resonances show a distinct pattern that can be separated using deconvolution algorithms such as LCModel.
In addition to the well-resolved glucose peak at 5.226 ppm, also detected and resolved at 4 T (52, 60), a distinct spectral representation of glucose was observed at 3.9 to 3.4 ppm in 9.4-T spectra from the rat brain. However, even under hyperglycemic conditions, the peak at 3.4 ppm is a triplet and thus closely resembles that of the taurine model spectrum as shown in Fig. 9 , further supporting the observation that the glucose signal is a minor constituent at this chemical shift in the brain (15, 61) . Detection of resolved glucose resonances may be critical in achieving the needed accuracy for glucose measurements by 1 H NMR. Extensions to other deconvolution methods are possible, although it remains to be demonstrated that other quantification methods, e.g., time domain fitting with prior knowledge (21, 62) , principal component (22) or wavelet analysis (23) , are able to handle such large sets of model spectra, containing multiple resonances, and that they are equally robust. It also remains to be shown whether the accuracy and efficiency of quantification of metabolites with low concentrations can be improved using alternate methods, which focus on the detection of selected metabolites, e.g., spectral editing of GABA (46) or using 2D fitting of multiple echo times (21) .
CONCLUSIONS
Ultrashort echo times combined with high sensitivity achieved at 9.4 T and excellent shimming maximize the spectral information in localized 1 H NMR spectra of the rat brain in vivo with minimal T 2 relaxation or J-modulation effects. We conclude that the in vivo spectra can be fully described by a superposition of 18 metabolite solution spectra and a macromolecule background with short T 1 relaxation times. This includes the simultaneous quantification of phosphocreatine, phosphorylethanolamine, GABA, glutathione, alanine, aspartate, resting lactate, and completely resolved glutamine in 1 H NMR spectra without any editing. Using high-field NMR with excellent shimming may lead to a noninvasive assessment of a significantly expanded neurochemical profile in vivo and timeresolved functional NMR spectroscopy (63) for the study of animal models of disease, e.g., hypoxia, stroke, or hepatic encephalopathy. Considering the significant resolution improvements with high static magnetic field shown in the human brain (26, 64, 65) , human studies should also benefit from increased magnetic fields. 
